IOF Positions and Statements

A new International Osteoporosis Foundation (IOF) position paper reviews experimental and clinical evidence showing that hip bone strength estimated by bone mineral density (BMD) and/or finite element analysis (FEA) reflects the actual strength of the proximal femur. Read more
In 2018 the International Osteoporosis Foundation (IOF) and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) published the updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Read more
The International Osteoporosis Foundation (IOF) welcomes the decision by the Committee for Medicinal Products for Human Use (CHMP), following a re-examination procedure, to grant a marketing authorisation for romosozumab in the treatment of severe postmenopausal osteoporosis. Read more
The impact of interruption of anti-osteoporosis treatment in patients on therapy with bisphosphonates or denosumab is reviewed in a new International Osteoporosis Foundation (IOF) working group paper 'Fracture risk following intermission of osteoporosis therapy' published in the journal Osteoporosis International.* Read more
Advances in the treatment of children and adolescents with cancer have led to substantial improvements in survival, with a 5-year survival rate of childhood cancer close to 80%. Read more
osteoporosis international, scientific peer-reviewed journal
Economic evaluations that compare interventions in terms of costs and outcomes are increasingly used by decision makers, with economic evaluations now playing an increasing role in pricing and reimbursement decisions. Read more
The widely reported message that vitamin D supplements are not needed, stemming from the recent publication by Bolland et al. in the Lancet Diabetes and Endocrinology, has caused much confusion and concern, particularly amongst older patients with osteoporosis. This statement sets out the response from the International Osteoporosis Foundation. Read more
El mensaje ampliamente divulgado de que los suplementos de vitamina D no son necesarios, como resultado de la reciente publicación de Bolland et al. en The Lancet Diabetes and Endocrinology, ha causado mucha confusión y preocupación, especialmente entre los pacientes mayores con osteoporosis. Esta declaración establece la respuesta de la International Osteoporosis Foundation. Read more
algorithm management of fracture risk in osteoporosis
Fragility fractures are a serious yet neglected complication of both type 1 and type 2 diabetes, with increased risk of fragility fractures in people with diabetes extending across the life span. Read more
osteoporosis international, scientific peer-reviewed journal
A new review, endorsed by the International Osteoporosis Foundation (IOF) and the European Society of Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), provides a succinct summary of several failings of the recent guidelines of the American College of Physicians (ACP) on the treatment of low bone density and osteoporosis. Read more


Subscribe to IOF Positions and Statements